stockrow
Friday 6 November 2026
Export ABT’s income statement to Excel — free account
Abbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- +28.9%
- Total debt
- +142.7%
Quarter to September 2026, against a year earlier
110.08
3.52
−3.10%
Follow ABT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
33.68 | 28.76 | 29.37 | 36.88 |
P/S ratio |
4.92 | 3.96 | 3.39 | 3.57 | |
P/FCF ratio |
29.50 | 24.25 | 20.18 | 21.98 | |
P/Operating CF |
65.80 | 136.05 | 63.48 | 69.13 | |
P/B ratio |
4.13 | 3.39 | 3.05 | 3.32 | |
Price to Tangible BV |
9.40 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.01 | 4.56 | 3.97 | 4.13 | |
EV/EBITDA |
19.89 | 18.92 | 17.14 | 18.44 | |
EV/Operating CF |
23.22 | 21.73 | 18.67 | 20.09 | |
EV/FCF |
30.04 | 27.87 | 23.64 | 25.44 | |
Quick Ratio |
1.02 | 0.84 | 0.80 | — | |
Current Ratio |
1.58 | 1.39 | 1.38 | — | |
Net Debt/EBITDA |
1.31 | 12.45 | 9.81 | — | |
Debt/Assets |
14.91% | 30.83% | 29.86% | — | |
Debt/Equity |
0.25 | 0.65 | 0.63 | — | |
Asset Turnover |
0.53 | 0.47 | 0.48 | 0.00 | |
Operating CF/Net income |
1.87 | 1.22 | 2.68 | 0.00 | |
Capex/Depreciation |
(0.87) | (0.50) | (0.47) | — | |
Interest Coverage |
18.76 | 7.73 | 4.82 | 4.57 | |
Research and Development Expense of Revenue |
6.41% | 6.87% | 7.08% | 7.07% | |
Selling, General and Administrative Expense of Revenue |
27.31% | 33.50% | 31.96% | 32.78% | |
Intangible Assets out of Total Assets |
0.34 | 0.48 | 0.48 | — | |
Share Based Compensation of Revenue |
0.99% | 2.84% | 1.33% | 0.00% | |
Graham Net Nets |
(0.04) | (0.18) | (0.21) | (0.19) | |
Graham Number |
50.37 | 49.29 | 45.47 | 0.00 | |
Earnings Yield |
2.97% | 3.48% | 3.41% | 2.71% | |
Free Cash Flow Yield |
3.39% | 4.12% | 4.95% | 4.55% | |
Revenue per Share |
6.58 | 6.41 | 7.24 | 0.00 | |
Operating CF per Share |
1.90 | 0.75 | 1.43 | — | |
Capex per Share |
(0.40) | (0.23) | (0.29) | — | |
Free Cash Flow per Share |
1.51 | 0.53 | 1.14 | — | |
Cash per Share |
5.13 | 4.19 | 3.22 | — | |
Shareholders Equity per Share |
30.31 | 30.24 | 29.74 | — | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
30.31 | 30.24 | 29.74 | — | |
Free Cash Flow |
2,626.00 | 916.00 | 1,991.00 | — | |
Working Capital |
9,500.00 | 7,131.00 | 6,703.00 | — | |
Capital Expenditures |
(689.00) | (399.00) | (497.00) | — | |
Net Current Asset Value |
(7,946.00) | (32,220.00) | (32,936.00) | — | |
EV/EBIT |
27.58 | 26.69 | 25.17 | 29.94 | |
Capex to Sales |
0.06 | 0.04 | 0.04 | 0.00 | |
Price to Operating Income |
27.09 | 23.22 | 21.50 | 25.88 | |
| Other line items | |||||
Average Receivables |
7,427.00 | 7,768.50 | 8,285.50 | — | |
Average Payables |
4,217.50 | 4,446.50 | 4,550.00 | — | |
Average Inventory |
6,341.00 | 6,814.00 | 7,134.50 | — | |
Average Assets |
84,063.50 | 95,938.50 | 96,607.00 | — | |
Average Common Equity |
50,336.00 | 50,882.50 | 51,295.50 | — |
Columns are period end dates · fundamentals updated 2 Nov 2026